Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push
Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025.…
Paternal sperm epigenetics may help explain early pregnancy loss
When a pregnancy ends early and unexplained, the search for answers usually begins with the mother. Lacey Luense,…
A scoping review on the mental health harms of LLM-based chatbots
Weizenbaum, J. ELIZA—a computer program for the study of natural language communication between man and machine. Commun. ACM…
Amylyx endocrine drug succeeds in key study for low blood sugar
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
Eli Lilly, Novo Nordisk earnings show widening divide in GLP-1 market
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters The diverging paths of…
Eli Lilly (LLY) earnings Q2 2026
Eli Lilly on Wednesday reported second-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook,…
Eli Lilly to offer retatrutide access given earlier to just one patient
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the…
7 life-saving medical innovations that could redefine healthcare
Over the past few years, several innovations have crossed important milestones, moving from experimental concepts toward real-world patient…
Eli Lilly will file for approval of retatrutide obesity drug in 2027
The Eli Lilly logo appears on the company’s office in San Diego, California, Nov. 21, 2025. Mike Blake…
AI-powered closed-loop wearable bioelectronics for personalized and autonomous healthcare
Chen, C., Ding, S. & Wang, J. Digital health for aging populations. Nat. Med. 29, 1623–1630 (2023). Article …
Ozempic for cats? GLP-1 weight-loss drugs are coming for your fat pet
A beautiful, but over weight Maine Coon Cat gets measured around the belly by a vet. Ryersonclark |…
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
AtaiBeckley’s lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly’s neuroscience pipeline…